The FDA has approved a new use for the drug Cosentyx (secukinumab). It can now be used to treat moderate to severe hidradenitis suppurativa, which is a long-term skin condition that causes painful lumps and abscesses, often in skin folds like the armpits or groin. This condition can significantly impact daily life.
This approval means Cosentyx is available for adults and children 12 years and older who have this condition. The drug works by targeting a specific protein in the body's immune system that contributes to inflammation. Doctors now have another treatment option to consider alongside existing therapies.
Cosentyx was already approved for several other inflammatory conditions like plaque psoriasis and psoriatic arthritis. The new approval provides an additional choice for patients and their healthcare providers when managing this challenging skin condition. Different dosing options are available depending on age and response to treatment.
It's important to remember that every medication affects people differently. While this approval expands treatment possibilities, it doesn't mean Cosentyx will work for everyone with hidradenitis suppurativa. Patients should have open conversations with their doctors about whether this treatment might be appropriate for their individual situation.
